Showing results (151-160 of 178) with videos related to
Sort By:
Pageof 18
JAMA Cardiology|October 11, 2018
Association of Unrecognized Myocardial Infarction With Long-term Outcomes in Community-Dwelling Older Adults: The ICELAND MI StudyTushar Acharya, Thor Aspelund, Torfi F Jonasson, et al.Cerebrovascular Diseases (Basel, Switzerland)|December 3, 2011
Polymorphisms and noncardioembolic stroke in three case-control studiesMay M Luke, Klaus Berger, Charles M Rowland, et al.The American Journal of Medicine|January 3, 2015
Beta-blocker Use and 30-day All-cause Readmission in Medicare Beneficiaries with Systolic Heart FailureVikas Bhatia, Navkaranbir S Bajaj, Kumar Sanam, et al.The American Journal of Cardiology|July 16, 2011
Relation of increased prebeta-1 high-density lipoprotein levels to risk of coronary heart diseaseLin T Guey, Clive R Pullinger, Brian Y Ishida, et al.Journal of the American College of Cardiology|September 19, 2015
Cardiovascular Effects of Exposure to Cigarette Smoke and Electronic Cigarettes: Clinical Perspectives From the Prevention of Cardiovascular Disease Section Leadership Council and Early Career Councils of the American College of CardiologyPamela B Morris, Brian A Ference, Eiman Jahangir, et al.International Journal of Cardiology|November 22, 2016
Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactonePhillip H Lam, Daniel J Dooley, Chakradhari Inampudi, et al.The American Journal of Medicine|October 18, 2024
Digoxin Discontinuation in Patients With HFrEF on Beta-Blockers: Implication for Future 'Knock-Out Trials' in Heart FailurePhillip H Lam, Kevin Liu, Amiya A Ahmed, et al.The Lancet. Diabetes & Endocrinology|September 21, 2017
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trialMarc S Sabatine, Lawrence A Leiter, Stephen D Wiviott, et al.Diabetes Care|June 22, 2025
Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER TrialYu Mi Kang, Robert P Giugliano, Xinhui Ran, et al.European Journal of Heart Failure|May 3, 2024
Identification and outcomes of KDIGO-defined chronic kidney disease in 1.4 million U.S. Veterans with heart failureSamir S Patel, Venkatesh K Raman, Sijian Zhang, et al.Pageof 18